Plus Therapeutics Expands ReSPECT Clinical Trial to MD Anderson Cancer Center (GlobeNewswire) - Dec 1, 2020 - "Plus Therapeutics, Inc...today announced that the University of Texas MD Anderson Cancer Center is now an active clinical trial site in its ongoing ReSPECT™ Phase 1 clinical trial, currently supported by the National Cancer Institute (NCI)...As the Company previously disclosed, the sixth dose escalation cohort of the ReSPECT trial is underway and expected to enroll by the end of 2020."
Trial status • Brain Cancer • Glioblastoma • Oncology
|